store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
E7820 (ER68203-00) 是具有口服活性芳香族磺酰胺衍生物,是一种血管生成抑制剂,可抑制内皮上整合素 α2 亚基的表达。它调节 α1,α2,α3 和 α5 整联素 mRNA 表达,具有抗血管生成和抗肿瘤活性。它抑制大鼠主动脉血管生成,IC50为 0.11 μg/ml。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 352 | 现货 | ||
2 mg | ¥ 473 | 现货 | ||
5 mg | ¥ 625 | 现货 | ||
10 mg | ¥ 828 | 现货 | ||
25 mg | ¥ 1,490 | 现货 | ||
50 mg | ¥ 2,230 | 现货 | ||
100 mg | ¥ 3,590 | 现货 | ||
200 mg | ¥ 5,120 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 867 | 现货 |
产品描述 | E7820 (ER68203-00) is an angiogenesis inhibitor by suppressing integrin a2 (a cell adhesion molecule expressed on endothelial cells). |
体外活性 | E7820 inhibits proliferation of HUVEC induced by either bFGF (IC50: 0.10 μg/mL) and VEGF (IC50: 0.081 μg/mL) in serum-free medium. E7820 also inhibits both bFGF- (IC50: 0.20 μg/mL) and VEGF-driven (IC50: 0.24 μg/mL) tube formation of HUVEC in this assay[3]. |
体内活性 | E7820 (50 mg/kg) with erlotinib has a significantly synergistic antitumor effect in three xenograft models without severe body weight loss. E7820 (50 mg/kg) and erlotinib decrease MVD and enhance apoptosis in tumor-associated endothelial cells, inhibit tumor cell proliferation and enhanced apoptosis, and enhance inhibition of cell proliferation and apoptosis through activation of both intrinsic and extrinsic apoptosis pathways in human NSCLC xenograft models[1]. E7820 shows anti-tumor activity at doses of 50, 100, and 200 mg/kg in the tumor growth and α2-integrin expression experiments[2]. E7820 (50, 100, and 200 mg/kg) inhibits tumor growth in a dose-dependent manner in all s.c. xenograft models. E7820 completely inhibits s.c. tumor growth of LoVo tumor cells and also regresses the tumor mass of KP-1 tumor cells at the dosages of both 100 and 200 mg/kg[3]. |
别名 | ER68203-00 |
分子量 | 336.37 |
分子式 | C17H12N4O2S |
CAS No. | 289483-69-8 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Insoluble
DMSO: 33 mg/mL
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
E7820 289483-69-8 Cytoskeletal Signaling Integrin cell tumor E 7820 WiDr derivative colorectal LoVo inhibit Inhibitor sulfonamide HUVEC ER68203-00 E-7820 endothelium inhibitor